- UBS Asset Management and Reef to develop major new campus for life science firms in Stevenage and provide up to GBP900m of new investment
- 1.4 million square feet of lab and office facilities to be created and space for up to 5,000 new jobs
- Development will be built alongside GSK’s existing Global R&D centre and Stevenage Bioscience Catalyst, the leading location for advanced therapeutics in the UK
UBS Asset Management’s Real Estate & Private Markets and Reef Group (Reef) today announce a joint venture as the investor and co-developer for a major campus for life science businesses in Stevenage, Hertfordshire. The new campus, which will be one of the largest of its kind in the UK and Europe, will be built alongside GSK’s existing Global R&D centre in the town. UBS Asset Management and Reef are expected to deliver up to GBP900m of new investment alongside an estimated 1.4 million square feet of laboratory and office facilities, providing space for up to 5,000 new jobs.
Plans for the campus were initially announced in 2021 and build upon the existing presence of both GSK and Stevenage Bioscience Catalyst (SBC), an organisation which provides a supportive environment for companies to develop and commercialise cutting edge advanced therapeutics. The campus is intended to help meet the growing demand for state-of-the-art commercial and laboratory space from both emerging and established life science firms.
UBS Asset Management and Reef, experienced life science investors and developers already delivering major life science development projects across the world with a Gross Development Value in excess of GBP5 billion, will begin construction of the new campus in 2023 and – subject to planning permission – intend to open some elements of the site for business by 2025.
UBS and Reef are set to purchase 33 acres of land from GSK to develop the new campus. As part of this, GSK will gift land on the new campus to SBC to enable its expansion. To support this expansion, GSK and the Wellcome Trust have also agreed to waive a loan which they made to SBC in 2012.
Stevenage is already home to a world-leading life science cluster, including more than 40 life science companies and the Cell and Gene Therapy Catapult. The vision for the new campus was developed in partnership with GSK, SBC, the UK Government, Stevenage Borough Council and the Hertfordshire Local Enterprise Partnership (LEP).
Jonathan Hollick, Head of Real Estate EMEA (ex-DACH), Real Estate & Private Markets, UBS Asset Management, said: “We’re very proud to be working alongside our development partner Reef, to create a globally renowned innovation campus and thank GSK for their support. The UK has a unique opportunity to be a world leader in life science, and we're committed to building on the excellent work that already takes place in Stevenage to support this ambition. We look forward to leveraging UBS’ expertise in building a sustainable centre of excellence that facilitates cutting edge R&D and creates thousands of skilled jobs."
Piers Slater, Joint Chief Executive, Reef Group said: “Stevenage is set to be transformed into one of the UK’s most dynamic life sciences hubs, forming an integral part of the eco-system of the Golden Triangle. We are excited to be working with UBS to deliver a unique and world-leading development that will be an incredible catalyst for innovation in life sciences R&D and thank GSK for their support. Our vision is to bring together the best of academia and industry in a diverse and world-class mix of life sciences spaces, with digital infrastructure, sustainability and connectivity at their core.”
Tony Wood, Chief Scientific Officer Designate, GSK said: “We are delighted by the news that UBS Asset Management and Reef are to develop this exciting new campus, which will be built next to our UK R&D hub in Stevenage. The campus will add much-needed laboratory space and facilities for new companies to locate here, and further strengthen the UK life science ecosystem. GSK invests around GBP1bn a year into R&D in the UK and continuing to expand our extensive network of collaborations is critical to our future success.”
Dr Sally Ann Forsyth OBE, Chief Executive Officer, Stevenage Bioscience Catalyst, said: “We welcome GSK’s land donation and the waiver of the original loan from GSK and the Wellcome Trust which supported the initial establishment and operations of SBC. These grants can now be used for the development of innovation facilities and related activities that enhance SBC’s offering as part of the new Campus development. The Stevenage campus is already a leading location for life science companies to develop and commercialise cutting edge therapeutics. It is a unique location that brings together major multinationals, the Cell and Gene Therapy Catapult Manufacturing Centre and Stevenage Bioscience Catalyst’s 40+ biotech companies. This makes it a powerhouse for innovation and we are looking forward to working with Reef Group and other stakeholders to further develop the thriving life sciences campus in Stevenage.”
Rishi Sunak, The Chancellor of the Exchequer, said: “The pandemic showed how important the health and life sciences sector is to our daily lives and the immense capabilities we have here in the UK. The investment in this major new campus will encourage companies to start, grow and invest in the UK, boosting jobs and the economy and cementing the country as a global life sciences hub.”
UBS provides financial advice and solutions to wealthy, institutional and corporate clients worldwide, as well as private clients in Switzerland. UBS's strategy is centered on our leading global wealth management business and our premier universal bank in Switzerland, enhanced by Asset Management and the Investment Bank. The bank focuses on businesses that have a strong competitive position in their targeted markets, are capital efficient, and have an attractive long-term structural growth or profitability outlook.
UBS is present in all major financial centers worldwide. It has offices in more than 50 regions and locations, with about 30% of its employees working in the Americas, 31% in Switzerland, 19% in the rest of Europe, the Middle East and Africa and 20% in Asia Pacific. UBS Group AG employs over 68,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).
UBS Asset Management
UBS Asset Management
Asset Management is a large-scale asset manager with a presence in 23 markets. It offers investment capabilities and investment styles across all major traditional and alternative asset classes to institutions, wholesale intermediaries and wealth management clients around the world. It is a leading fund house in Europe, the largest mutual fund manager in Switzerland, the second largest fund of hedge funds manager and one of the largest real assets investment managers in the world.
Reef Group was founded in 2001 and has grown to become one of the UK’s leading development and regeneration experts, with extensive experience in large scale mixed-use development. Reef Group are passionate about design, planning, and regeneration, collaborating with local authorities, occupiers and investors to deliver sophisticated developments and vibrant experiences that stimulate towns and cities throughout the UK. Its in-house design and delivery team, Urban R, supports their passion for development of best in class assets and transforming the way people use and experience place.
Reef Group is now the UK’s leading developer of life sciences regeneration projects in the UK, with over 3.5 million sq ft of developments underway in London, Oxford, Cambridge, and Stevenage. It has built a specialist team with a deep understanding of the life sciences industry from both a commercial and technical perspective. Across all asset classes, Reef Group’s portfolio consists of over 6 million sq ft of space currently under development or in planning. Its goal is to create vibrant mixed-use developments across life sciences, hotels, student accommodation, leisure, retail, residential, offices, and technology.
For more information visit
About the Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is a world-leading science park of global significance and located at the centre of the largest cluster of cell and gene therapy companies in Europe. It provides a supportive environment to help companies grow by providing access to specialist equipment, mentoring and finance suited to their stage of development. Since its opening in 2012, occupier companies have secured GBP2.9bn in finance making the cluster one of the most attractive for investment in biotechnology in the UK.
GSK is a science-led global healthcare company. For further information please visit
Wellcome is a charity that supports science to solve the urgent health challenges facing everyone. SBC is a non-profit company with a vision of accelerating the translation of cutting-edge science to improve the health and quality of people’s lives. Wellcome’s waiver of its GBP1.6m loan to SBC will enable the company to expand its support for life sciences start-ups to bring their discoveries into use and thereby improve human health. Wellcome is a founding member of SBC. Helping to stimulate translational research is one of many ways Wellcome supports the life sciences research ecosystem in the UK and around the world.
Make an inquiry
Fill in an inquiry form and leave your details – we’ll be back in touch.
Introducing our leadership team
Meet the members of the team responsible for UBS Asset Management’s strategic direction.
Find our offices
We’re closer than you think, find out here